Page 574«..1020..573574575576..580590..»

Most Dog Breeds Are Really Inbred | Smart News – Smithsonian

Posted: December 10, 2021 at 2:33 am

To understand the full effect of inbreeding in all dog breeds, the research team partnered with Wisdom Health Genetics, the largest dog DNA database in the world, to collect data and information from 49,378 dogs ranging across 227 breeds. Lua Bittencourt via Wikimedia Commons under CC BY 2.0

When looking to add a canine companion to the family, somepeople already have a specific breed in mind. But manydogs' distinctive featureslikea black-and-white Dalmatian's spotsor a French bulldog's stubby snoutare the result of remarkably high levels of inbreeding,according to a studypublished this month inCanine Medicine and Genetics.Overall, scientists found the average level of inbreeding was around 25 percent, which is the same level of genetic similarity siblings usually share, reports Ed Cara forGizmodo.

Most modern dog breeds were established within the last 200 years. Through the use of studbooks to ensure pure-bred pedigrees in the last100 years, inbreeding has become the norm in manybreeds. At the behest of genetics, these inbred animalsespecially large dogsdevelop chronic health issues, which contribute to costly vet bills over their lifespan.

To understand the full effect of inbreeding in all dog breeds, the research team partnered with Wisdom Health Genetics, the largest dog DNA database in the world, to analyze genetic data from 49,378 dogsacross 227 breeds. The data is mainly compiled from European sources, according to astatement.

The levels of inbreeding found in the data are higher than what would be considered safe for wild animal populations and humans. In humans, inbreeding levels between 3 percent and 6 percent result in higher chances of cancer or hereditary disorders, perGizmodo.

Researchers then took this data and cross-referenced it withpet insurance claims for non-routine visits using adatabase fromAgria Insurance Sweden. Together, the data shows dog breeds with high levels of inbreeding were more likely to visit the vet than dogs that were not inbred,Gizmodoreports.

Some dog breeds are more inbred than others because breeders select for specific traits based on how it makes a dog look.For example, smaller dog breeds like Shih Tzus and pugs are bred to have extremely short snoutsoften, to the point where they appear flat-faced. These breeds are technically brachycephalic, which means they are predisposed to respiratory issues, perGizmodo. On average, brachycephalic dogs were less healthy than non-brachycephalic dogs.

While previous studies have shown that small dogs live longer than large dogs, no one had previously reported on morbidity or the presence of disease," says study author Danika Bannasch, a veterinary geneticist at the University of California, Davis,in astatement. "This study revealed that if dogs are smaller and not inbred, they are much healthier than larger dogs with high inbreeding.

A small founding population of abreed was also linked to high levels of inbreeding, while breeds with large founding populations had more genetic variation. Many breeds with large founding populations were originally bred fortheir function and intelligencenot for their looks. For example, the healthiest breed studied wasDanish-Swedish farm dogs, which originated from a sizeable founding population of 200 dogs. These dogs were bred for hunting, keeping guard, and tracking.

Its amazing how inbreeding seems to matter to health, says Bannasch.

The team emphasizes that careful management of breeding populations is needed to preserve genetic diversity in canines. This goal can be achieved by using genetic screening, educating breeders, and maintaining diversity in pups with low inbreeding levels.

Recommended Videos

Visit link:
Most Dog Breeds Are Really Inbred | Smart News - Smithsonian

Posted in Genetics | Comments Off on Most Dog Breeds Are Really Inbred | Smart News – Smithsonian

Maximizing the Use of Genetic Data Will Pay Dividends – Drovers Magazine

Posted: December 10, 2021 at 2:33 am

The Angus University: Genetics workshop sponsored by Zoetis at the 2021 National Angus Convention and Trade Show served as an educational session to inform breeders about the value of collecting genetic data and ways to use it in decision making.

The panel included moderator, Kelli Retallick-Riley, president of Angus Genetics Inc. (AGI), and four panelists Justin Sexten, vice president of strategy and product development for Performance Livestock Analytics; Jim Moore of Moore Cattle Company, a commercial Angus operation; James Henderson of Bradley 3 Ranch, an Angus seedstock operation; Troy Marshall, director of commercial industry relations for the American Angus Association.

Understanding and valuing genetic data can present as a daunting task to seedstock and commercial producers alike. Retallick-Riley asked panelists to describe how they use genetic data to navigate breeding decisions and market cattle to the next industry segment.

Being able to have some prediction of what those cattle are really worth and being able to get that kind of value out of them and they perform accordingly makes it better for all of us, Henderson said. We can sit down with an individual customer and say, Heres where you are today, heres where you want to be and heres what its going to take to do that.

Sometimes the primary struggle with data stems from the collection process. Sexten emphasized how modern technology provides breeders with the tools to efficiently collect data, document it and convey the information to each sector of the supply chain.

From a technology perspective, we think about it as how do I take the notes you take on a cow thats locked up in text messages, snapshots on your phone and notes on a piece of paper thats thrown up on the dash and convey that up and down the supply chain in a way that the association can make predictions from it, Sexten said. I think technology provides us the ability to convey information across all of these segments. So thats how we think about it is how can we convey information, not just gather more and more data.

Marshall encouraged the use of programs like AngusLinkSM which provides commercial producers the opportunity to maximize data collection efforts and more importantly, maximize profits.

Those buyers up and down the chain need information, they need market flexibility, market access, and theyre looking to mitigate their risk and these programs give them that, Marshall said. As a result, AngusLink has helped to capture more premiums. This last year, the people enrolled in the AngusLink program had an average return of about $84 over the market. Over the last three years, weve returned almost $12.5 million in premiums to commercial producers. I think this information flow is just going to continue to grow.

In addition to the AngusLink program, the GeneMax Advantage test allows commercial cattlemen to receive genetic information on unregistered females to make strategic decisions when selecting replacements.

I think one of the underutilized things about [GeneMax Advantage] is if you know what youre replacing, you also know what bulls to select, so you get a double advantage, Moore said. I think that GeneMax Advantage just gives you the opportunity to differentiate yourself in the marketplace and objectively describe the cattle so you can capture the value they deserve.

The role genetic data plays in any operation will likely continuously increase over time. Henderson said if you havent already, the time to start using genetic data to enhance your decision making is now.

I think if you're not looking at genetic information today in your herd, whether youre a commercial or a seedstock operation, youre probably falling behind very quickly, Henderson said. Its time to get into the education process and figure out where you are from a genetic standpoint.

See the original post here:
Maximizing the Use of Genetic Data Will Pay Dividends - Drovers Magazine

Posted in Genetics | Comments Off on Maximizing the Use of Genetic Data Will Pay Dividends – Drovers Magazine

Geneticists Have Reduced Use of the Term ‘Race’ in Papers – Medscape

Posted: December 10, 2021 at 2:32 am

A decline in the use of the word "race" in papers on human genetics reflects a growing understanding of race as a social construct. But other trends may point to ongoing uncertainty about how to discuss different populations.

What to know:

Human geneticists have moved away from using the word "race" to describe populations, a study recently published in The American Journal of Human Genetics (AJHG) shows.

Researchers examined the text of all 11,635 articles published between 1949 and 2018 by the AJHG. While the word "race" appeared in 22% of papers in the first 10 years of the paper's publication, it was used in just 5% of papers in the last 10 years.

This decline points to the current understanding in science of race as a social construct and a desire to move away from past research that erroneously conflated genetics with racial categories, according to lead author Vence Bonham, JD, the acting deputy director of the National Human Genome Research Institute.

The study also found that the alternative and sometimes more ambiguous terms "ethnicity" and "ancestry" have increased over time, which may suggest that geneticists are still struggling to find terms to accurately describe populations.

A The National Academies of Science, Engineering, and Medicine has recently formed a committee to produce a consensus report on the use of the word "race" and other terms descriptive of populations in health disparities research.

This is a summary of the article "Human geneticists curb use of the term 'race' in their papers" published by Science on December 2. The full article can be found on science.org.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, andLinkedIn

Excerpt from:
Geneticists Have Reduced Use of the Term 'Race' in Papers - Medscape

Posted in Human Genetics | Comments Off on Geneticists Have Reduced Use of the Term ‘Race’ in Papers – Medscape

SomaLogics SomaScan Assay used in largest proteomic study to date, bridging the gap between genomics and disease – Yahoo Finance

Posted: December 10, 2021 at 2:32 am

BOULDER, Colo., Dec. 09, 2021 (GLOBE NEWSWIRE) -- In a new study published in Nature Genetics, scientists at deCODE genetics, a subsidiary of Amgen, used SomaLogics (NASDAQ: SLGC) SomaScan Assay to measure blood proteins in 35,559 Icelanders and mapped them to 27 million genetic sequence variants. Using this vast amount of proteomic data, these researchers hope to demonstrate that combining protein measurements at population scale with genetic data on disease will dramatically impact understanding of human diseases and potential drug targets. This new study was the largest proteomic study published to date with 170 million protein measurements.

Less than 10% of human disease is driven by genetics. Plasma proteomics, the study of blood proteins, can help bridge the gap between genomics and disease discovery. This paper found that linking genes to proteins, and then to diseases can show patterns between the factors that cause a disease and the factors that are a consequence of a disease. This process may give a roadmap of how diseases develop and offer potential drug targets.

In this study, the plasma levels of 4,719 blood proteins were tested for genetic associations with 373 diseases and traits, producing 257,490 of these associations. SomaLogics SomaScan Assay was used to find genetic variant-protein target associations, called protein quantitative trail loci or pQTLs. In the study, 94% of the proteins measured using the SomaScan Assay showed an associated pQTL, resulting in more than 18,000 pQTLs. Ninety-three percent of these pQTLs are considered novel. The study also identified 938 genes encoding as potential protein drug targets for various diseases.

Our SomaScan Assay offers the ability to measure and identify the largest percentage of the human proteome at commercial scale on the market today and it proved to be exquisitely specific in this study, said SomaLogic Chief Executive Officer Roy Smythe, M.D. We hope that this study, and more like it, will help to provide the vital information that can be added to genetic data to create a more comprehensive understanding of human biology, and increasingly power more effective treatments for human disease.

Story continues

About SomaLogicSomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogics personalized measurement of important changes in an individuals proteins over time. For more information, visit http://www.somalogic.com and follow @somalogic on Twitter.

Forward Looking Statements Disclaimer This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed business combination between SomaLogic and CM Life Sciences II and otherwise, including statements regarding the anticipated benefits of the business combination, the anticipated timing of the business combination, expansion plans, projected future results and market opportunities of SomaLogic. These forward-looking statements generally are identified by the words believe, project, expect, anticipate, estimate, intend, strategy, future, opportunity, plan, may, should, will, would, will be, will continue, will likely result, and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogics or CM Life Sciences IIs control. You should carefully consider the risks and uncertainties described in the Risk Factors section of the CM Life Sciences IIs registration statement on Form S-4 (File No. 333-256127) (the Registration Statement) and the definitive proxy statement/prospectus included therein. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic and CM Life Sciences II assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither SomaLogic nor CM Life Sciences II gives any assurance that either SomaLogic or CM Life Sciences II or the combined company will achieve its expectations.

SomaLogic Contact Emilia Costales 720-798-5054ecostales@somalogic.com

Investor ContactLynn Lewis or Marissa BychGilmartin Group LLCinvestors@somalogic.com

Read the original:
SomaLogics SomaScan Assay used in largest proteomic study to date, bridging the gap between genomics and disease - Yahoo Finance

Posted in Human Genetics | Comments Off on SomaLogics SomaScan Assay used in largest proteomic study to date, bridging the gap between genomics and disease – Yahoo Finance

Is There a Genetic Link to Being an Extremely Good Boy? – WIRED

Posted: December 10, 2021 at 2:32 am

Flash isnt your average puppy. A yellow Labrador, named after one of the first British guide dogs from 1931, she is playful, affectionate, and loves learning new commands. Flash is enrolled in an elaborate program herself, one that takes two years and nearly $50,000 to train her to become a guide dog for the blind and visually impaired. Her temporary caregiver Melanie will make sure she maintains a healthy routine: twice-daily walks in different environments, a train ride here, a trip to a mall there to get used to other people. But Melanie has already accomplished one of her most important tasks: When Flash was five months old, she swabbed the puppys cheek and mailed the saliva away to a team of researchers that is trying to decipher the link between dog genetics, health, and behavior.

Around half of the dogs that are bred for guiding dont end up doing that work because of health or behavioral problems. Modern dogs suffer from many genetic diseases, a side effect of keeping breeds separate and selecting them for desirable traits. Some of these purebreds might have the right looks, but not the right temperament, to become a working dog. But what if breeders could predict what makes a good guide dog and select against undesired traits, ensuring they arent passed on to the next generation?

More than 500 traits analogous to human genetic conditions have been described in dogsboth species can suffer from cancer, eye disease, or dysplasia of the hip, to name a few. Cheap DNA tests for canines can screen for changes, known as mutations, in a single gene. The causes of many other conditions, however, are more complex. They can be linked to multiple genes or to environmental factors like exercise, food, dust, or mold spores. We definitely want to get a handle on complex traits, says Tom Lewis, head of canine genetics at Guide Dogs. The charity breeds around 1,000 puppies a year, which spend their first year in the homes of volunteers before entering formal training.

Before joining Guide Dogs in January, Lewis worked at the Animal Health Trust and the Kennel Club in the United Kingdom, where he studied the genetic risk of hip dysplasia in breeds registered with the club. Dysplasia is one of the hereditary conditions that can be difficult to diagnose and treat. It is a malformation of the hip joint that develops during growth, though traumatic injury, being overweight, or lacking muscle strength can worsen the condition. For example, puppies raised in homes with hardwood flooring may build less muscle mass in their legsthey cant get traction on the floor, and slip and slide around, which is hard on their little joints. The constant pain can eventually turn into lameness and arthritis in grown dogs, making them unsuitable for guiding or assisting people with disabilities.

Good health is key for guide dogs, but temperament is just as important. They need to lead their owners around obstacles and other people while staying calm and obedient. They need to resist chasing after squirrels or getting too excited when meeting other dogs. Not every breed has what it takes. For example, the typical cocker spaniel is intelligent, affectionate, and a great option for families, but it is also too excitable. Even if you give them the same training, you would never expect a spaniel to be a guide dog. They're far too temperamentally unsuited, and that's probably a genetic thing, says Lewis.

Go here to see the original:
Is There a Genetic Link to Being an Extremely Good Boy? - WIRED

Posted in Human Genetics | Comments Off on Is There a Genetic Link to Being an Extremely Good Boy? – WIRED

Toward a genome sequence for every animal: Where are we now? – pnas.org

Posted: December 10, 2021 at 2:32 am

Abstract

In less than 25 y, the field of animal genome science has transformed from a discipline seeking its first glimpses into genome sequences across the Tree of Life to a global enterprise with ambitions to sequence genomes for all of Earths eukaryotic diversity [H. A. Lewin etal., Proc. Natl. Acad. Sci. U.S.A. 115, 43254333 (2018)]. As the field rapidly moves forward, it is important to take stock of the progress that has been made to best inform the disciplines future. In this Perspective, we provide a contemporary, quantitative overview of animal genome sequencing. We identified the best available genome assemblies in GenBank, the worlds most extensive genetic database, for 3,278 unique animal species across 24 phyla. We assessed taxonomic representation, assembly quality, and annotation status for major clades. We show that while tremendous taxonomic progress has occurred, stark disparities in genomic representation exist, highlighted by a systemic overrepresentation of vertebrates and underrepresentation of arthropods. In terms of assembly quality, long-read sequencing has dramatically improved contiguity, whereas gene annotations are available for just 34.3% of taxa. Furthermore, we show that animal genome science has diversified in recent years with an ever-expanding pool of researchers participating. However, the field still appears to be dominated by institutions in the Global North, which have been listed as the submitting institution for 77% of all assemblies. We conclude by offering recommendations for improving genomic resource availability and research value while also broadening global representation.

The first animal genome sequence was published 23 y ago (1). The 97 millionbasepair (bp) (Mb) Caenorhabditis elegans genome assembly ushered in a new era of animal genome biology where genetic patterns and processes could be investigated at genome scales. As genome assemblies have accumulated for an increasingly diverse set of species, so too has our knowledge of how genomes vary and shape Earths biodiversity (e.g., refs. 2 and 3). Major shifts in genome availability and quality have been driven by two key events. First, the invention of high-throughput, short-read sequencing provided an economical means to generate millions of reads for any species from which sufficient DNA could be obtained. These 100-bp short reads could be assembled into useful, albeit fragmented, genome assemblies. Later, the rise of long-read sequencing allowed for similarly economical generation of reads that are commonly orders of magnitude longer than short reads, resulting in vastly more contiguous genome assemblies (4).

We have now entered an era of genomic natural history. Building on 250 y of natural history efforts to describe and classify the morphological diversity of life on Earth, we are gaining a complementary genomic perspective of Earths biodiversity. However, a baseline accounting of our progress toward a complete perspective of Earths genomic natural historywhere every species has a corresponding, reference-quality genome assembly availablehas not been presented. This knowledge gap is particularly important given the momentum toward sequencing all animal genomes, which is being driven by a host of sequencing consortia. For instance, the Vertebrate Genomes Project seeks to generate high-quality assemblies for all vertebrates (5), the Bird10K project seeks to generate assemblies for all extant birds (6), the i5K project plans to produce 5,000 arthropod genome assemblies (7), the Earth BioGenome Project aims to sequence all eukaryote genomes (8), and the Darwin Tree of Life project plans to sequence genomes for all eukaryotes in Britain and Ireland (https://www.darwintreeoflife.org/).

In this Perspective, we curated, quantified, and summarized genomic progress for a major component of Earths biodiversity: kingdom Animalia (Metazoa) and its roughly 1.66 million described species (9). We show that as of June 2021, 3,278 unique animals have had their nuclear genome sequenced and the assembly made publicly available in the National Center for Biotechnology Information (NCBI) GenBank database (10). This translates to 0.2% of all animal species. When viewed through the lens of major clades, massive disparities exist. For instance, 32 times more assemblies are available for chordates than arthropods (Fig. 1).

Variation in taxonomic richness and genome availability, quality, and assembly size across kingdom Animalia in GenBank (as of 28 June 2021). Taxonomic groups are clustered by phylogeny following ref. 11. Only groups with 30 or more available assemblies as of January 2021 are shown with the exception of Hominidae (n = 5 assemblies). In the tree, bold group names represent phyla and naming conventions follow those of the NCBI database. Of 34 recognized animal phyla, 10 do not have a representative genome sequence. (A) The total number of described species for each group following Zhang (9) and the references therein. (B) Genomic representation among animal groups for 3,278 species with available genome assemblies. Bars represent the magnitude of the observed minus the expected number of genomes given the proportion that each group comprises of described animal diversity. Significance was assessed with Fishers exact tests and significantly under- or overrepresented groups (P < 0.05) are denoted with asterisks. Gray numbers indicate the total number of species with available genome assemblies for each group. The number of available assemblies is not mutually exclusive with taxonomy; that is, a carnivore genome assembly would be counted in three categories (order Carnivora, class Mammalia, phylum Chordata). (C) The percentage of described species within a group with an available genome sequence (bars) and the percentage of those assemblies that have corresponding annotations (red circles). For many groups (e.g., arthropods), only a fraction of a percent of all species have an available genome assembly, making their percentage appear near zero. (D) Assembly size for all animal genome assemblies, grouped by taxonomy. (E) Contig N50 by taxonomic group. The sequencing technology used for each assembly is denoted by circle fill color: short-read (blue), long-read (yellow), or not provided (gray). In D and E, each circle represents one genome assembly and a few notable or outlier taxa are indicated with gray text.

To construct a database of the best available genome assembly for all animals, we downloaded metadata from GenBank for all kingdom Animalia taxa using the summary genome function in v.10.9.0 of the NCBI Datasets command-line tool on 4 February 2021. Next, we used the TaxonKit (12) lineage function to retrieve taxonomic information for each taxid included in the genome metadata. To gather additional data for each assembly (e.g., sequencing technology), we used a custom web scraper script. Both this web scraper script and the scripts used to download and organize the metadata are available in this studys GitHub repository (https://github.com/pbfrandsen/metazoa_assemblies). We later supplemented this initial dataset with a second round of metadata acquisition on 28 June 2021. For the full dataset, we hand-refined the NCBI taxonomy classifications to subdivide our dataset into three categories: species, subspecies, or hybrids (Dataset S1). If replicate assemblies for a taxon were present, we defined the best available assembly as the one with the highest contig N50 (the midpoint of the contig distribution where 50% of the genome is assembled into contigs of a given length or longer).

We filtered our data in several ways: We removed subspecies (unless they were the only representative for a species), hybrids, and assemblies that were shorter than 15.3 Mb [the smallest confirmed assembly size for a metazoan to date (13)] or had a contig N50 less than 1 kilobase (Kb). We also culled assemblies that were unusually short (i.e., 1 to 2.5 Mb) with information in their descriptions that indicated they were not true nuclear genome assemblies (e.g., exon capture). In total, we culled 407 assemblies based on the above criteria. The remaining assemblies were classified as short-read, long-read, or not provided if only short reads (e.g., Illumina) were used, any long-read sequences (e.g., PacBio) were used, or no information was available. We defined a species as having gene annotations available if any assembly for that taxon also had annotations in GenBank. When the best available assembly did not have annotations included or when multiple assemblies had annotations, we retained the annotations for the assembly with the highest contig N50. Finally, we used the submitting institution for each assembly as a surrogate for the institution that led the genome assembly effort. Using these data, we classified assemblies to a country, region (Africa, Asia, Europe, Middle East, North America, Oceania, South America, Southeast Asia), and the Global North (e.g., Australia, Canada, Europe, United States) or Global South (e.g., Africa, Asia including China, Mexico, Middle East, South America).

To test if clades were under- or overrepresented in terms of genome availability relative to their species richness, we compared the observed number of species with assemblies with the expected total for the group. We obtained totals for the number of described species overall and for each group from previous studies, primarily from Zhang (9) and the references therein. We assessed significance between observed and expected representation with Fishers exact tests (alpha = 0.05). We tested for differences in distributions of contig N50 or assembly size between short- and long-read genomes with Welchs t tests. For both display (i.e., Fig. 1) and analysis, we subdivided the dataset into the lowest taxonomic level that still contained 30 or more assemblies as of January 2021 (with the exception of hominids, which were given their own category due to their exceptionally high genomic resource quality).

Genome assemblies were available for 3,278 species representing 24 phyla, 64 classes, and 258 orders (Fig. 2A and Dataset S1). The dataset was exceptionally enriched for the phylum Chordata (which includes all vertebrates) with 1,770 assemblies for the group (54% of all assemblies) despite chordates comprising just 3.9% of animal species (P, Fishers < 1e-5; Fig. 1). Conversely, arthropods were underrepresented with 1,115 assemblies (34% of the dataset) for a group that comprises 78.5% of animal species (P, Fishers < 1e-5; Fig. 1). However, not all arthropods were underrepresented; five insect clades were overrepresented (Apidae [bees], Culicidae [mosquitoes], Drosophila [fruit flies], Formicidae [ants], and Lepidoptera [butterflies and moths]; all P, Fishers < 1e-3; Fig. 1). Collectively, of the 59 animal taxonomic groups included in our dataset, 14 groups were underrepresented, 17 were represented as expected, and 28 were overrepresented (primarily chordates; Fig. 1). Ten phyla had no publicly available genome sequence (Fig. 1). Over the 17-y GenBank genome assembly record, animal assemblies have been deposited at a rate of 0.52 species assemblies per day. Over the most recent year, however, this rate increased eightfold to 4.07 assemblies per day. If the most recent rate were maintained, all currently described animals would have a genome assembly available by 3136. To achieve this goal by 2031 instead, an average of 165,614 novel animal genomes would need to be sequenced and assembled each year (112 times faster than the rate for the most recent year).

Genome availability for kingdom Animalia versus taxonomic descriptions and over time. (A) The proportion of described taxonomic groups versus the number with sequenced genome assemblies from phyla to species. The gray plot (Right) is a zoomed-in perspective of the higher taxonomy-level categories in the full plot (Left). For genus through phylum, the number of described categories is based on the NCBI taxonomy. For species, the total number described is from Zhang (9). (B) The timeline of genome contiguity versus availability for animals according to the GenBank publication date (x axis; C). A rise in assembly contiguity has been precipitated by long-read sequencing. Particularly contiguous assemblies for a given time period are labeled. (C) The number of animal genome assemblies deposited in GenBank each month since February 2004. Several notable events are labeled. When specific dates are indicated, those (and the assemblies referred to) are included within that months total. For B and C, it is important to note that when a genome assembly is updated to a newer version, its associated date is also updated. Thus, the date associated with many early animal assemblies [e.g., C. elegans (1)] has shifted to be more recent with updates.

The average animal genome assembly was 1.02 gigabases (Gb) in length (SD 1.21 Gb) with a contig N50 of 2.26 Mb (SD 25.16 Mb; Fig. 1 D and E). Two animal genome assemblies were 25 Gb longer than all other assembliesthe axolotl [32.4 Gb (14)] and Australian lungfish [34.6 Gb (15)] (Fig. 1D). The smallest genome assembly in the dataset, the mite Aculops lycopersici, was over 1,000 times smaller, spanning just 32.5 Mb (16). Still smaller is the 15.3 Mb assembly of the marine parasite Intoshia variabili, which has the smallest animal genome currently known (13). But, since the I. variabili assembly was not available in GenBank as of June 2021, it was not included in our dataset.

Contiguity varied dramatically across groups. For instance, hominid assemblies (family Hominidae, n = 5) were the most contiguous with an average contig N50 of 24.2 Mb. Bird assemblies (class Aves, n = 515) were also highly contiguous (mean contig N50 = 1.4 Mb) despite being so numerous (and accumulating over a long period of time). On the other end of the spectrum, jellyfish and related species (phylum Cnidaria) exhibited some of the least contiguous genome assemblies with a mean contig N50 of 0.18 Mb (n = 65; Fig. 1E). Roughly 34% of animals with genome assemblies had corresponding annotations in GenBank but annotation rates differed substantially among groups (Fig. 1C). For example, the rate of arthropod annotations (22.3%) lags behind that for chordates (41.3%); however, much of this disparity appeared to be driven by the low and high annotation rates of butterflies and moths (order Lepidoptera) and birds (class Aves), respectively. Of 445 assemblies, just 6.5% of lepidopteran assemblies in GenBank have corresponding annotations versus 72.8% of birds (n = 519 assemblies; Fig. 1C). Notably, since most gene models are based on sequence similarity to known functional genes and not functional data, the true rate of annotation is likely even lower than reported here.

Animal genome assemblies have been contributed by researchers at institutions on every continent with permanent inhabitants, including 52 countries. From a regional perspective, institutions in North America (n = 1,331), Europe (n = 972), and Asia (n = 828) collectively accounted for 95.5% of all assemblies (Fig. 3A). And, nearly 70% of all animal genome assemblies have been submitted by researchers in just three countries: United States (n = 1,275), China (n = 676), and Switzerland (n = 317) (Fig. 3A). When countries were grouped by their inclusion in the Global North or South, similarly stark patterns emerged. Researchers affiliated with institutions in the Global North contributed roughly 75% of animal genome assemblies (Fig. 3B). From a taxonomic perspective, researchers at North American institutions have contributed the most insect and mammal assemblies, European researchers have contributed the most fish assemblies, and Asian researchers have contributed the most bird assemblies (Fig. 3A). The first assembly in GenBank from the Global North was deposited in 2004 and the first assembly from the Global South was deposited in 2011 (Fig. 3C). Since then, the number of assemblies deposited each year has steadily risen, with the proportions from the Global North and South staying relatively constant (Fig. 3C).

Where animal genome assemblies have been produced around the world according to the submitting institutions in GenBank. (A) For each geographic region, total numbers of genome assemblies are shown by dark circles with white lettering. This total is further broken down by country and taxon. For regions where more than four countries have contributed assemblies (e.g., Europe), an Other category represents all other countries. The same applies to all assemblies that are not insects, birds, fish, or mammals in the taxon plots. Countries are color-coded by assignment to the Global North or South. (B) The total number of genome assemblies contributed by countries in the Global North (e.g., United States, Europe, Australia) versus the Global South (e.g., Africa, South America, China, Mexico, Middle East). (C) The rate of genome assembly deposition by major sources in the Global North (Europe, United States) and Global South (China, Southeast [SE] Asia) as well as all other countries collectively in each (Other).

Use of long reads in genome assemblies and availability of key metadata also differ with geography. For assemblies deposited since 2018, researchers from the Global South have used long reads slightly more frequently than those from the Global North (25.7% versus 20.2%; Fig. 4A). However, researchers from the Global North were far less likely to report the types of sequence data used (19.9% of assemblies for the Global North versus 1.4% of assemblies for the Global South; Fig. 4A). Much of this difference appears to be driven by genome assemblies deposited by researchers at European institutions (Fig. 4B). This gap in metadata may reflect an issue with data mirroring between the European Nucleotide Archive (ENA) and GenBank. For instance, many new genome assemblies being generated by the United Kingdom, for example, are part of the Wellcome Sanger Institutes Darwin Tree of Life project, which is generating exceptionally high quality assemblies using long-read sequencing and depositing them into the ENA (Fig. 5). One region (Oceania) and three countries (Australia, Finland, India) reported long reads being used in more than 50% of deposited assemblies (Fig. 4 B and C).

Sequencing technologies used around the world (A) between the Global North versus Global South, (B) among regions, and (C) among countries. To limit bias due to the limited availability of long-read sequencing technologies before 2017 (Fig. 2B), only assemblies deposited on or after 1 January 2018 were included in the analysis and in C only countries that deposited five or more assemblies during the focal period (January 2018 to June 2021) are shown.

Examples of major contributors of genome assemblies for (A) butterflies (order Lepidoptera), (B) birds (class Aves), and (C) fish (primarily class Actinopterygii). Major contributors were defined as any consortium, organization, or project that has deposited more than 5% of all assemblies for butterflies and birds or 2.5% of all assemblies for fish.

Animal genome sequencing has dramatically progressed in the last 25 y. In that span, the field has moved from sequencing the first nuclear genome for any animal (1)a landmark achievementto targeting the generation of genome assemblies for all of Earths eukaryotic biodiversity (8). Here, we provided a contemporary perspective on progress toward this goal for the 1.6 million species in the animal kingdom (9). We showed that while tremendous progress has been made, major gaps and biases remain both in terms of taxonomic and geographic representation, at least within the most commonly used database of genomic resources, GenBank. For instance, a major bias exists in favor of vertebrates which are vastly overrepresented relative to their total species diversity (Fig. 1 AC). From the perspectives of biomedicine and human evolution, this bias is reasonable since humans are vertebrates. However, from a basic research perspective, particularly as it relates to genomic natural history and an overarching goal to sequence all animal genomes, there is a need to taxonomically diversify sequencing efforts.

At the highest taxonomic levels, 10 animal phyla still have no genomic representation. To illustrate the scale of this disparity versus other groups and the unique biology that is being overlooked, genome assemblies are available for 685 ray-finned fishes (class Actinopterygii) but none exists for phylum Nematomorpha, an 2,000-species clade of parasitic worms whose presence can dramatically alter energy budgets of entire stream ecosystems (17). Another phylum without genomic representationLoriciferawas first described in 1983 (18). This group of small, sediment-dwelling animals includes the only examples of multicellular species that spend their entire life cycles under permanently anoxic conditions (19). Loriciferans accomplish this feat by foregoing the energy-producing mitochondria found in virtually all animals in favor of hydrogenosome-like organelles akin to those found in prokaryotes inhabiting anaerobic habitats (19). Clearly, there is much to discover in terms of genomic diversity and functional biology in clades yet to be sampled.

A few select countriesprimarily the United States, several European nations, and Chinahave led the sequencing of the vast majority of animal genome assemblies (Fig. 3A). Aside from China, all of these countries are within the Global North. This pattern of geographic bias raises two potential issues for representation in animal genome science. First, the researcher population of animal genome sequencing likely does not reflect the global population. Second, sampling biases may exist toward the regions where most of the genome sequencing is occurring. Some of this bias is intentional and reflects funding goals for a given region. For instance, the Darwin Tree of Life project seeks to sequence the genomes of all 70,000 eukaryotic species living in Britain and Ireland. Still, however, similar to how sampling biases can yield skewed understanding of the natural world in other disciplines (e.g., ref. 20), so too could bias toward specific ecoregions, habitats, or other classifications skew genomic insight.

Inherently linked with questions of representation in animal genome science is the specter of parachute science (or helicopter research)the practice where international scientists, typically from wealthy nations, conduct studies in other countries that are often poorer without meaningful communication nor collaborations with local people (21). Parachute science has a long history in ecological research, and signatures of these practices have been observed for genome sciences. For instance, Marks etal. (22) found that the majority of plant genome assemblies for species that are native to South America and Africa were sequenced off-continent by researchers at European, North American, or Asian institutions. Given the sheer number of animal genome assemblies that have been submitted by a small number of countries and institutions, a similar pattern likely exists for animal genomes. However, to properly assess this issue, parsing authorship to quantify collaboration, at a minimum, would need to occur and this approach would still overlook key aspects of representation that need to be considered (e.g., if a researcher from the Global South is working at an institution in the Global North).

For the purpose of biological discovery, not all genome assemblies are created equal. As long-read sequencing technologies have matured, so too has the quality of assemblies being generated (4). In the last year alone, the largest ever animal genome assembly was deposited [Australian lungfish (15)] as well as the most complete human genome to date, a telomere-to-telomere assembly (23). Still, many species in GenBank only have low-quality assemblies available (i.e., contig N50 < 100 Kb with no corresponding gene annotations; Fig. 1). Since fragmentation and/or poor or missing gene annotations reduce the research value of an assembly, genome quality is important, particularly when the end goal is resource development for a broader community. As of April 2021, the Earth BioGenome Project sought assembly quality of 6.C.Q40 (https://www.earthbiogenome.org/assembly-standards) for reference genomes, where 6 refers to a 1e-6 contig N50 (i.e., 1 Mb). In our dataset, 568 assemblies (17.3%) reach this contiguity standard. And that number drops to 271 assemblies (8.3%) when contig N50 1 Mb and deposited gene annotations are both required. For reference, the C above refers to chromosomal scale scaffolding and Q40 to a less than 1/10,000 error rate. Neither of these metrics were assessed in this study.

Independent research laboratories, institutions, and consortia have contributed genome assemblies on both ends of the quality spectrum (Fig. 5). For example, among butterflies (order Lepidoptera), a bimodal quality distribution is being primarily driven by contributions made in 2021 by two submitting institutions, the Florida Museum of Natural History (e.g., ref. 24) and the Wellcome Sanger Institute (Fig. 5A). When viewing genome assembly contributions holistically across the animal Tree of Life, it is clear that two consortiathe Vertebrate Genomes Project (5) and the Darwin Tree of Life, part of the Wellcome Sanger Institutewarrant specific recognition for contributing exceptional genomic resources relative to closely related species (Fig. 5).

While animal genome science has dramatically matured in recent years, the field still rests on the cusp of massive change. Thousands of genome assemblies are now available for a wide range of taxa, a resource that can empower unprecedented scales of genomic comparison. Simultaneously, multiple consortia are building momentum toward their goals and generating some of the highest-quality genome assemblies ever produced. The field is also diversifying, with researchers around the world, particularly from the Global South, leading a rising number of efforts. These ongoing advances will yield higher-quality, more globally representative genome data for animals. As we collectively build toward this new genomic future, we offer recommendations to improve assembly quality and accessibility while also continuing to increase representation within the discipline.

The quality of a genome assembly is likely the most important factor dictating its long-term value. Genome assembly quality, however, is difficult to define. Here, we propose a holistic view on genome assembly quality that generally echoes the guidelines proposed by the Earth BioGenome Project and other consortia. Briefly, assemblies should reach minimum levels of contiguity (e.g., contig N50 > 1 Mb) and accuracy in order to be considered a reference that will likely not need to be updated for most applications. At a minimum, assemblies should also include high-quality gene annotations that perhaps take advantage of standardized pipelines [e.g., NCBI Eukaryotic Genome Annotation Pipeline (25)] to maximize compatibility across taxa. We recommend the field further improve the quality of genome assembly resources in two ways. First, refining and expanding the coordinated deposition of genome assemblies will improve the usability of the resources and reproducibility of analyses. It will also reduce duplications of effortthat is, when a group sequences a genome that has already been producedan issue that is likely to become increasingly common.

To refine and expand coordinated resource deposition, we recommend the continued use of GenBank (10) or one of the other archives that are members of the International Nucleotide Sequence Database Collaborationthe ENA and DNA Database of Japanas the central repositories for genome assemblies and their metadata given their tripartite data-sharing agreement. Next, we call on genetic archive administrators, consortia, and independent researchers to collectively improve the metadata submitted with each assembly and the mirroring of data across repositories. Too many assemblies lack basic information about the sequence data and methods used (e.g., Fig. 4) and, with the difficulty of linking assemblies to published studies (if available), it can be challenging or impossible to find this information. Further, an expansion of the metadata associated with each assemblyideally to make more of the categories required and expand demographic datawould make efforts to quantify geographic representation, for instance, far more straightforward. Alternatively, the metadata associated with genome assembly accessions could be integrated with existing efforts like the Genomic Observatories Metadatabase [GeOMe (26)]. Furthermore, a set of minimum quality characteristics for a genome assembly may need to be defined. A number of exceptionally low quality genome assemblies (e.g., with contig N50 values shorter than 1 Kb) that often cover only a small fraction of the expected total genome sequence length for a given group are present in GenBank. The presence of these assemblies raises the question: Where is the inflection point between resource quality and value to other researchers versus diluting the resources of a shared repository?

For our second recommendation, we amplify and expand the message of Buckner etal. (27) and Thompson etal. (28): Genome science needs specimen vouchers. Vouchers serve as a key physical link between taxonomy and molecular insight. Rarely, however, are vouchers referenced in publications of genome assemblies; only 11% of vertebrate assemblies included such a reference as of January 2020 (27). While vouchers represent a physical reference for assessing taxonomic classification or morphological variation, a properly stored voucher could also provide a long-term source of material for future resource improvement. If a physical specimen cannot be deposited, photographs and/or genomic DNA should be deposited in its place (e.g., ref. 29). Tied to the metadata discussion above, additional fields should be added to GenBank genome assembly accessions to directly link the assembly to a specimen, photo, or genomic DNA that has been deposited elsewhere.

Though geographic representation in animal genome science has improved in recent years, the discipline appears far from properly reflecting the global researcher pool. This issue is almost certainly multifaceted, likely stemming from a lack of infrastructure (e.g., fewer high-throughput sequencing platforms in developing countries), fewer resources for expensive molecular research, and a corresponding lack of training in genome data analysis. To bridge this gap and to empower a more diverse discipline, the nations and institutions that are devoting large amounts of resources to animal genome sequencing (e.g., China, United Kingdom, United States), and the researchers within those countries, should continue to develop meaningful collaborations with researchers within countries where their focal species reside (30). These meaningful collaborationswhere all parties are valued for their expertise and involved in decision makingimprove the science through transfer of local knowledge, provide a means for local researchers to expand their skillset and network while raising their scholarly profile, and, most importantly, can effectively end the practice of parachute science (30). Within-continent (or -country) initiatives also have transformative potential for people and genome research. For instance, the African-led effort to sequence 3 million African genomes over the next 10 y (the 3MAG project) will yield massive investment in African genomics, an incredible resource for understanding the full scope of human genetic diversity, and a new generation of African genome scientists (31). While focused on human genetics, the infrastructure and expertise that arise from the 3MAG project will no doubt translate to other taxa in the coming years.

A practical justification also exists for increasing representation in genome science, particularly as we seek to generate genome assemblies for every animal on Earth. The Global South is home to the bulk of the worlds biodiversity (32) and, as such, researchers in these regions have greater access to key habitats and specimens. Thus, it behooves everyone, including researchers in the Global North, to deepen collaborations with peers in the Global South while also helping to build indigenous capacity for collection, storage, and sequencing of new specimens.

Animal genome science continues to grow and expand at an exceptional rate. The coming years will surely see thousands, and perhaps tens of thousands, of new genome assemblies from across the Tree of Life, technological and analytical improvements, and some of the largest-scale and most in-depth studies of animal genome biology conducted to date. However, if we are to realize the ambitious goals of efforts like the Earth BioGenome Projecta self-described biological moonshotthe rate and mean quality of animal genome assembly production will have to increase by roughly two orders of magnitude. Regardless of rates and timelines, however, perhaps the most important goal for the future of animal genome science is that we empower a more diverse, representative researcher community in parallel with the generation of new resources.

All study data are included in the article and/or supporting information.

S.H. and J.L.K. were supported by NSF Award OPP-1906015. We thank Guangfeng Song, Eric Cox, and Anne Ketter from the Datasets development team at the NCBI for their responsiveness and receptiveness to improving this valuable tool for data science.

Author contributions: S.H., J.L.K., and P.B.F. designed research; S.H. and P.B.F. performed research; S.H. and P.B.F. analyzed data; and S.H., J.L.K., and P.B.F. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2109019118/-/DCSupplemental.

See the article here:
Toward a genome sequence for every animal: Where are we now? - pnas.org

Posted in Human Genetics | Comments Off on Toward a genome sequence for every animal: Where are we now? – pnas.org

WesCeleb Caroline Pitton ’22: The Short One with Bangs Who Works in Admissions – Wesleyan Argus

Posted: December 10, 2021 at 2:32 am

c/o Caroline Pitton

One of the best known faces to students even before they enroll at the University, Caroline Pittons 22 smiling face framed by her famous bangs is plastered on the wall of the admissions office, where she can frequently be found when she is not working in a research lab, TAing, or singing. The Argus caught up with Pitton to talk about her time on campus and her future beyond it.

The Argus: Why do you think you were nominated to be a WesCeleb?

Caroline Pitton: I was genuinely so surprised when you told me cause I dont think I know enough people to be a WesCeleb. I feel like I just walk around and recognize most people that pass me, but I think I have a very public-facing job. I work as a senior interviewer in the Office of Admission, and Ive worked in admissions since literally the first week of my freshman year. I used to plan WesFest and Open House, and now I talk to prospective students a lot. That job is the most fun place to work on campus. Everyone who works there is so outgoing and friendly. I also TA a lot so if you took intro bio or intro chem or some French classes, chances are youve seen me as your TA.

A: What are your majors?

CP: Im a biology and French double major with an informatics and modeling minor. I came into Wesleyan knowing I wanted to do biology, and then my pre-major advisor was a French professor and that was a happy accident. Then, I did my minor almost completely by accident. One day [I] was talking to another bio major and figured out that Id done five of the six credits for [the modeling] minor.

A: Did you speak French prior to coming to Wes?

CP: My moms entire extended family lives in France. They do not speak English whatsoever, so she spoke to me in French when I was a baby, and that kind of tapered off, especially when my brother was born and life got wild. I went to a French and English school and all of the kids who went there only spoke French, so I really had to learn how to speak, to communicate with my classmates. I wasnt super invested in the study of French language and culture until I got a couple years into college and I realized how fun it is to speak another language and think about cultures that arent those that youve grown up in.

A: How did you know you wanted to be a bio major?

CP: I was really supported in my science classes in middle and high school. I thought I might want to be a math major at some point but I took intro bio as a freshman in my first semester. I went in and I was like, I think I wanna be a bio major, but if I hate intro bio, its okay to change my mind. I loved it, but I think its not a given that biology majors like intro bio [because] our intro bio curriculum is challenging and fast-paced and intense. Every bio class Ive taken since then Ive liked even more. Its my favorite academic discipline in the world. I could talk your ear off about biology. Thats what I want to do academically and career-wise in the future. Biology is what I want to think about every day.

A: Have you had a favorite class or professor at Wesleyan?

CP: My favorite professor at this university is Professor Joe Coolon in the Biology department. Hes my research advisor. Ive been in his lab since I was a sophomore and we study genomics in fruit flies and yeast. He is one of the best teachers and academic mentors I could ever ask to have. Every time I talk to him, he makes me so excited about science. He has this really infectious energy. He always wants to know whats going on, with my work but also with my life and with my future plans. And he creates a really fun lab environment where everyone works together really well and is genuinely friends in and outside of the work environment.

A: What are you researching?

CP: I spent my whole junior year and the summer after my junior year researching a system in fruit flies that we can use to turn on and off the expression of specific genes, which is very niche. But I looked at this one system and I did a lot of bioinformatics analysis and then I finished that project over the summer, and now Im working on a few other projects. They all have to do with what happens when we expose fruit flies to different environmental toxins, like pesticides, and what happens in the fruit fly genome. Like, which genes get turned on? Do some genes turn on more than other genes? Do they turn off? How do those genes interact?

A: What else are you involved with on campus?

CP: Up until this semester, I sang with Onomatopoeia, the acapella group. I had to take a step back from that this semester, but that was one of the most formative and most fun parts of my college experience. I also music directed two shows for Second Stage my freshman and sophomore years. The friends that I made doing theater and acapella, I still hold so closely.

A: You mentioned that you started working in admissions the first week of [your first] year. How did that happen?

CP: I walked on campus and I was like, okay, I need to find a work-study job. And they have a job fair with a table for admissions. I was like, that seems like a fun place to work. As a [first year], its one of the only offices at Wesleyan that you are aware exists because its the office that you interact with before you are a student. I literally just filled out an application for a random job, which happened to be the intern job, which is event planning mostly. I met a lot of really cool people through it, and working in the Office of Admission gives you a really nice support network of other students, but also the professional adult staff that work there. Going to work three times a week and seeing the same people and having office chit-chat and building those relationships that still exist three years later was really stabilizing.

A: What are your plans after graduation?

CP: Im going to be a research associate in a lab at the Dana Farber Cancer Institute in Boston. Im working in a lab that studies the genetics and genomics of blood cancers. Im also really lucky that I found a job this early. Its a lot of biology concepts that I learn about and I practice in my undergraduate lab and classes, but its applied to medicine and to people in a way that we dont do at Wesleyan, which is really exciting to me as someone that wants to work more in medical research and human genetics in the future.

A: How do you think your friends would describe you?

CP: They make fun of me for how much I talk about flies, but also people know me as having bangs. So when we have conversations about how my housemates describe each other to people that dont know us, I am the short one with bangs who works in admissions.

A: Did you ever not have bangs?

CP: I have quite literally never not had bangs. At my first haircut where I had a substantial amount of hair, my mom said, I think bangs would be cute. And I was two years old, and now Im 21 and I still have bangs. I considered growing them out during COVID-19, but then I had an identity crisis. And I was like, Im gonna come back for my junior year in a mask and Im not gonna have bangs. No one will recognize me; the bangs have to stay.

A: Do you have a favorite Wesleyan story?

CP: One that really stuck with me, especially during COVID-19, was in February of 2020. Ono and Slender James threw a kegcert, which is a concert with a keg in a Fauver. It was the weekend before spring break and it was probably the most fun concert that wed ever done in anyones memory of people that were in Ono at the time. The singing, I think, was good, but it was more like, the energy was really exciting and it was a packed Fauver. All of our friends were there and were screaming and people were dancing. I remember finishing that concert and everyone in Ono was like, That was so fun. We have to do that again. Then obviously we all went home and [didnt come] back. I think for a long time, especially last year when no one was socializing, that was something that I really held onto as being like the last real party that I had been to. And it was such funthere was nothing bad about that night.

A: What are you most proud of in your time at Wes?

CP: Im really proud of how I pushed myself out of my comfort zone to try new things during my time at Wesleyan. I didnt become complacent. I mentioned doing student theater. I had never done theater before college. That was totally out of my comfort zone, and Im so glad I did it. I had so much fun and I learned a lot. Same with research. I didnt think I wanted to do research and then I tried it, and now its literally what Im doing for a job next year. And same with the French major. I had never thought of myself as a humanities person, and now I read French literature.Im proud that I didnt box myself into only doing one thing and how much I got to learn from my peers at Wesleyan. I think that other students are what make this place so special. Im glad that I really took advantage of getting to know everyone around me.

This interview has been edited for length and clarity.

Hallie Sternberg can be reached at hsternberg@wesleyan.edu.

View original post here:
WesCeleb Caroline Pitton '22: The Short One with Bangs Who Works in Admissions - Wesleyan Argus

Posted in Human Genetics | Comments Off on WesCeleb Caroline Pitton ’22: The Short One with Bangs Who Works in Admissions – Wesleyan Argus

UAB researcher shines light on a rare disease that causes developmental and intellectual delays – The Mix

Posted: December 10, 2021 at 2:32 am

After years of researching the SON gene,Erin Eun-Young Ahn, Ph.D., may have found the cause behind an extremely rare disease.

After years of researching the SON gene, Erin Eun-Young Ahn, Ph.D., may have found the cause behind an extremely rare disease.(Photography: Nik Layman)Since the early 2000s, Erin Eun-Young Ahn, Ph.D., associate professor in theUniversity of Alabama at BirminghamDepartment of PathologysDivision of Molecular & Cellular Pathology, has been studying the SON protein and gene. The SON gene makes a protein, also called SON, that is required for the body to develop and grow normally. While Ahn is one of the worlds leading experts on the SON gene, she had no idea that her work would ultimately help determine the cause behind an extremely rare disease known as Zhu-Tokita-Takenouchi-Kim syndrome.

ZTTK syndrome is a severe multi-system developmental disorder characterized by delayed psycho-motor development and intellectual disability. Common clinical features of ZTTK include intellectual and developmental delays, brain malformations, muscle abnormalities and facial asymmetry. Little is known about this disease, including its cause, until Ahn discovered that ZTTK syndrome is the result of a genetic mutation of the SON gene.

Ahns journey began in 2014 when a physician from California contacted her about a pediatric patient who suffered from developmental and intellectual disabilities. These included late milestones in language and cognitive processing. Ahn has published research showing that SON function is important in the RNA editing step, called RNA splicing. RNA delivers instructions to cells from DNA on which proteins to produce. The physician found Ahns postdoctoral research publication and reached out for help.

The patient underwent standard genetic testing panels and tests for gene mutations on known genes, which all came back normal. Finally, the doctors ran exome sequencing a test developed in the last decade that can identify more undiscovered variants in an unbiased way. They found that the only gene mutation this patient had was in the SON gene.

This was the first finding of this specific gene mutation in humans, Ahn said. We knew that SON is overexpressed in several types of cancer cells, but we didnt know whether the mutations in the DNA sequence of the SON gene that cause loss-of-function really existed in the human patient. It was really eye opening.

Ahn made a case report on this single patient, showing how in cancer there is an overproduction of SON, and with an underproduction, there are developmental and intellectual delays like those present in the first patient. The journal to which she submitted the work suggested she locate other cases. With the assistance of a website tracking undiagnosed diseases and a database of gene mutations, Ahn found a few more incidents indicating DNA sequence changes in the SON gene. She reached out to those patients physicians and the involved researchers in the U.S. and Europe, finding they had the same symptoms as her original pediatric patient.

We went from one case to five cases, Ahn said. And a few months after that, the information began to spread rapidly. Clinicians and genetic counselors started talking, and the information became international.

Ahns group eventually analyzed clinical symptoms of 20 patients who carry mutations in the SON gene. They also conducted experiments using the cells obtained from the patients and demonstrated that an insufficient amount of the SON protein leads to defective RNA splicing in patients, which in turn causes abnormal brain development and metabolism. Their findings were published in the journal,American Journal of Human Genetics, in September 2016. The publication played a major role in designating this new disease caused by SON mutations as ZTTK syndrome.

Typically, the human body houses two copies of the SON gene, and Ahn found that those with ZTTK have one copy of the normal SON gene and one copy of the mutated SON gene. This mutation in the SON gene means that the body cannot produce as much of the SON protein needed for its cells to develop properly. This lack of cell development leads to the developmental and intellectual delays found in patients with this disease. There are currently no reported cases of mutations found in both copies of the SON gene, which suggests that mutations in both copies may be extremely detrimental to human development.

The mutations show up during development but are not inherited from the parents, which is why awareness of the syndrome by clinicians is key to connecting patients with resources, Ahn said. They have to talk to their doctor and a genetic counselor and get the exome sequencing done to get the diagnosis.

In her role as one of the worlds primary researchers on the SON gene, Ahn became a point of contact for patients and their families, connecting families all over the world. This led to the establishment of a Facebook group for the syndrome, which now has more than 245 members. Last year, several of the parents of children, together with Ahn, created theZTTK SON-Shine Foundationthat showcases personal stories of families learning how to live with this syndrome.

We developed the ZTTK SON-Shine Foundation, because we wanted to create a sense of community among people affected by this disease so they do not feel isolated, Ahn said. This is a way that parents of children with ZTTK can help and share information with each other in hopes of improving the quality of life for every patient with ZTTK syndrome.

In addition to connecting families with this challenging rare disease, the foundation hopes to spread awareness of the syndrome to clinicians in particular.

One of the goals of the ZTTK SON-Shine Foundation is making a network of clinicians and researchers who can share their expertise to help the families affected by this syndrome, Ahn said. Exome sequencing reports typically indicate the results in scientific terms, but when patients receive those, they dont understand what that means. So, I often provide the families with an explanation of what these genetic codes mean in laymans terms, so that they can have a clear understanding. I am very grateful that I have opportunities to help the patients and families.

Ahn is no longer alone in the study of ZTTK, but working with researchers across the globe on different manifestations of this syndrome in patients, from issues ranging from bone development to kidney function to metabolism and the immune system.

We hope some part of our finding will contribute to a medical treatment, Ahn says, And we know our findings can provide them with information. We dont know whether we can find a cure, but if we know more about how SON mutation affects patients metabolism, kidney issues, bone structure, neurological features, and immune system, we can do a lot for patient care and prevention and alleviate their symptoms.

Go here to read the rest:
UAB researcher shines light on a rare disease that causes developmental and intellectual delays - The Mix

Posted in Human Genetics | Comments Off on UAB researcher shines light on a rare disease that causes developmental and intellectual delays – The Mix

Alpha-1 Biologics Announces Positive Data Published in frontiers in Oncology on Alphataxin in Combination with Anti-PD-1 Therapy that Suppressed…

Posted: December 10, 2021 at 2:32 am

Study showed the potential of Alphataxin, an orally available, small-molecule drug that elevates tumor-infiltrating CD4+ T cells to treat renal cancer

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Alpha-1 Biologics, a biotherapeutics company developing innovative treatments for cancers and immune deficiencies, today announced that positive data was published in frontiers in Oncology demonstrating Alphataxin, a small molecule that elevates circulating and tumor-infiltrating CD4+ T cells, suppressed kidney cancer and suppressed metastasis in mice. Orally available Alphataxin, is the first and only drug in development to increase formation of CD4+ helper T cells. Immune checkpoint inhibitor therapy, the vanguard of cancer therapy, promotes the ability of CD8+ T cells to kill tumor cells. However, CD8+ T cells are unable to kill tumor cells in the absence of chemical mediators secreted by CD4+ helper T cells. The data showed that Alphataxin treatment is efficacious as a monotherapy in kidney cancer in mice and enhances anti-PD-1 immune checkpoint inhibitor therapy, with the potential to expand the number of human cancer patients who respond to checkpoint inhibitor therapy.

Cynthia L. Bristow, PhD, CEO of Alpha-1 Biologics said, We are excited to announce this positive pre-clinical data, which showed that Alphataxin, orally delivered in combination with an injected immune checkpoint inhibitor, may provide a powerful approach that can produce long-term remission in kidney cancer and other T cell-responsive tumors. Alphataxin as a monotherapy and in combination with anti-PD-1 immune checkpoint inhibitor therapy significantly suppressed tumor growth in a mouse model of kidney cancer and significantly elevated the number of circulating and tumor-infiltrating CD4+ T cells.

In the study, following implantation of mouse kidney tumor cells within the kidney of mice, combination treatment of Alphataxin and anti-PD-1 therapy resulted in 100% elimination of tumor growth. Moreover, in mice implanted with ten times more tumor cells into the kidney, doubling the Alphataxin dose in combination treatment with anti-PD-1 led to 100% elimination of tumors in one-third of mice and 81% suppression of tumor growth in the remaining two-thirds of mice. Both anti-PD-1 and Alphataxin monotherapy showed decreased tumor growth as compared with untreated mice. Lung metastasis was present in monotherapy but eliminated in combination-treated mice.

The study also investigated the effects of Alphataxin on the immune system in healthy mice. The data showed that Alphataxin increased the normally circulating numbers of CD4+ T cells, Pre-T cells, and CD4/CD8 ratio indicating that Alphataxin acts to increase the formation of CD4+ helper T cells.

This combination treatment of Alphataxin with an anti-PD-1 therapy addresses a high unmet medical need in patients with kidney cancer who have very low survival rates. The 5-year survival rate for patients with renal adenocarcinoma undergoing anti-PD-1 treatment is estimated to be 27.7%. However, despite the efficacy of checkpoint inhibitors in promoting the cytotoxic activities of tumor infiltrating CD8+ T cells, approximately 87% of cancer patients do not respond to immune checkpoint therapy, said Dr. Bristow. Kidney cancer is often not diagnosed until after metastasis, a disease stage for which there are few effective treatment options; however, recent promising advances demonstrate that easily accessible blood-based tests provide early detection, and this means that Alphataxin has the potential to be transformative in providing long lasting remission in kidney cancer.

Ron Winston, President, Institute for Human Genetics and Biochemistry said, We are pleased with these pre-clinical results, which have further increased our confidence in the promising potential of Alphataxin to treat cancers and immune deficiencies. Based on this positive data, the company plans to raise additional capital to rapidly advance the Alphataxin development program.

The full article in frontiers in Oncology can be accessed here: Alphataxin, a Small-Molecule Drug That Elevates Tumor-Infiltrating CD4+ T Cells, in Combination With Anti-PD-1 Therapy, Suppresses Murine Renal Cancer and Metastasis.

About Alphataxin

Alpha-1 Biologics discovered that the protein alpha-1 proteinase inhibitor (1PI, alpha-1 antitrypsin) regulates the number of circulating CD4+ T cells by stimulating the locomotion of Pre-T cells. The orally available small-molecule drug Alphataxin acts as a surrogate for 1PI in this pathway. The Company is focused on the development of Alphataxin, which suppressed tumor growth in a mouse model of kidney cancer. Alphataxin, in combination with anti-PD-1 antibody, significantly elevated circulating and tumor-infiltrating CD4+ T cells. Because orally available Alphataxin is the first and only drug developed to increase CD4+ T cells, Alphataxin is eligible for FDA Breakthrough Designation. In combination with anti-PD-1, Alphataxin is a powerful therapeutic method that provides long-term remission in kidney cancer in mice and is being tested in other T cell-responsive cancer models.

About Alpha-1 Biologics

Alpha-1 Biologics was founded by Cynthia L. Bristow, PhD, in 2011 for the purpose of developing patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of 1PI, and in the most prevalent cause of immune deficiency, malnutrition. The research to discover a therapy to elevate the number of CD4+ helper T cells was inspired by a desire to provide treatment for HIV-infected childhood orphans in subSaharan Africa. The idea for how to develop a therapy was discovered by comparing HIV-infected patients with healthy individuals. In two clinical trials using FDA-approved 1PI therapy, the number of CD4+ T cells were increased in HIV-infected patients and in uninfected healthy volunteers. Based on those studies, the Company is focused on developing orally available drugs to stimulate locomotion of helper T cells and Pre-T cells to treat cancer and immune deficiency. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005360/en/

Read the original post:
Alpha-1 Biologics Announces Positive Data Published in frontiers in Oncology on Alphataxin in Combination with Anti-PD-1 Therapy that Suppressed...

Posted in Human Genetics | Comments Off on Alpha-1 Biologics Announces Positive Data Published in frontiers in Oncology on Alphataxin in Combination with Anti-PD-1 Therapy that Suppressed…

Inspiring Young Female Doctors in the UAE and Beyond – APN News

Posted: December 10, 2021 at 2:32 am

Published on December 10, 2021

SKMCs Dr. Shaden Abdelhadi shares the story of her prolific career and how support from SEHA is helping women working in healthcare achieve their dreams

Abu Dhabi Health Services Company (SEHA), the UAEs largest healthcare network, is continuing with its efforts to propel the careers of young and ambitious female doctors.

Setting an example of perseverance and sheer determination, coupled with excellence in her field, is Dr. Shaden Abdelhadi, FRCP (Edin), FAAD is an internationally trained Emirati Pediatric Dermatologist specializing in human genetic skin disorders at the Genetic Pediatric Dermatology Unit at Sheikh Khalifa Medical City (SKMC), part of SEHA.

Dr. Abdelhadi said: To women in medicine, I urge you to continue persevering, irrespective of the challenges you may encounter. Forge ahead and never lose sight of the patients whose health we strive to better every single day. I consider myself supremely lucky to have received the right support during my career. I joined SEHA in 2005 as a Staff Physician in the Department of Medicine at SKMC. The tremendous support I have received in terms of training, access to opportunities and resources, played a major contributing role in where I stand today as a dermatologist.

One of the most respected medical professionals working in her area of expertise, Dr. Abdelhadi acknowledges how education has shaped her career. I consider it an absolute privilege to have had such an extensive education. From becoming a Department of Health (DoH) Specialist through the Arab Board Dermatology Residency Program at SKMC in 2012, to gaining clinical training experience at the Childrens Hospital of Washington University in Seattle, and St. Thomas Hospital in London, every step has added a new dimension to my clinical understanding.

Gaining the Postgraduate Belgium Board Certificate in Pediatric Dermatology (2017) and the Interdisciplinary Board Certificate in Human Medical Genetics (2018) were both challenges that bolstered my self-confidence. In my line of work, real-world experience is an absolute necessity, and I am truly grateful for having received it through my fellowships with the Royal College of Physicians, Edinburgh; American Academy of Dermatology; European Academy of Dermatology and Venereology; and the European Society of Pediatric Dermatology.

Dr. Abdelhadi is currently a member of the International Society of Pediatric Dermatology and a member of the Editorial Board of Dermatologic Therapy, one of Europes leading scientific publications. She was recently elected to the UAE Dermatology Specialty Committee, which is leading the future of postgraduate education in dermatology in the UAE.

Despite having reached the zenith of professional success, Dr. Abdelhadi maintains there is no greater joy than to teach. What use is a wealth of knowledge if one isnt willing to share it? I am currently an Assistant Professor of Dermatology at the College of Medicine and Health Sciences, Khalifa University in Abu Dhabi, and a core faculty member at the Arab Board Dermatology Residency Program at SKMC. I thrive on the discussions I have with my students; it keeps adding a fresh perspective to my understanding of medicine.

I am passionate about disseminating national and international education in the treatment of pediatric dermatology and pediatric genetic skin diseases. In my opinion, medical education never ceases, you must constantly keep yourself updated. Since 2016, I have been the co-founder and Vice President of several annual international pediatric dermatology conferences precisely for this reason.

Dr. Abdelhadi is a leading figure in helping SEHA deliver excellence in healthcare. She has been instrumental in efforts to have the Arab Board Dermatology Residency Program at SKMC accredited by the American Council for Graduate Medical Education (ACGME), making it the worlds second US accredited dermatology residency program outside the USA. Furthermore, she also set up the UAEs first Multidisciplinary Epidermolysis Bullosa Center.

Speaking about the immense support she has received at SEHA, Dr. Abdelhadi said: SEHA has played a key role in my training and supported my ambition of becoming a uniquely specialized physician. With SEHA being a leader in medical education, I believe I can work closely with the National Institute of Health Sciences in better planning the medical specialties and sub-specialties the UAE needs.

Dr. Abdelhadis route to success, however, has not been without challenges, with slow and bureaucratic processes, changing priorities and decisions all hurdles that needed to be overcome.

There is no success without challenges, she said. To all the budding female doctors in the region, I hope my journey serves as a reminder that nothing is impossible if you have enough perseverance.

See the rest here:
Inspiring Young Female Doctors in the UAE and Beyond - APN News

Posted in Human Genetics | Comments Off on Inspiring Young Female Doctors in the UAE and Beyond – APN News

Page 574«..1020..573574575576..580590..»